Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bronte, V.
Right arrow Articles by Zanovello, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bronte, V.
Right arrow Articles by Zanovello, P.
[Cancer Research 60, 253-258, January 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Genetic Vaccination with "Self" Tyrosinase-related Protein 2 Causes Melanoma Eradication but not Vitiligo1

Vincenzo Bronte2, Elisa Apolloni, Roberto Ronca, Paola Zamboni, Willem W. Overwijk, Deborah R. Surman, Nicholas P. Restifo and Paola Zanovello

Department of Oncology and Surgical Sciences University of Padova, 35128 Padova, Italy [V. B., E. A., R. R., P. Z., P. Z.], and Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [W. W. O., D. R. S, N. P. R.]

"Self" melanocyte differentiation antigens are potential targets for specific melanoma immunotherapy. Vaccination against murine tyrosinase-related protein (TRP)-1/gp75 was shown recently to cause melanoma rejection, which was accompanied by autoimmune skin depigmentation (vitiligo). To further explore the linkage between immunotherapy and autoimmunity, we studied the response to vaccination with a related antigen, TRP-2. i.m. inoculation of plasmid DNA encoding murine trp-2 elicited antigen-specific CTLs that recognized the B16 mouse melanoma and protected the mice from challenge with tumor cells. Furthermore, mice bearing established s.c. B16 melanomas rejected the tumor upon vaccination with a recombinant vaccinia virus encoding trp-2. Depletion experiments showed that CD8+ lymphocytes and natural killer cells were crucial for the antitumor activity of the trp-2-encoding vaccines. Mice that rejected the tumor did not develop generalized vitiligo, indicating that protective immunity can be achieved in the absence of widespread autoimmune aggression.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Kottke, L. Sanchez-Perez, R. M. Diaz, J. Thompson, H. Chong, K. Harrington, S. K. Calderwood, J. Pulido, N. Georgopoulos, P. Selby, et al.
Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer
Cancer Res., December 15, 2007; 67(24): 11970 - 11979.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kianizad, L. A. Marshall, N. Grinshtein, D. Bernard, R. Margl, S. Cheng, F. Beermann, Y. Wan, and J. Bramson
Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope
Cancer Res., July 1, 2007; 67(13): 6459 - 6467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Nair, D. Boczkowski, M. Fassnacht, D. Pisetsky, and E. Gilboa
Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity
Cancer Res., January 1, 2007; 67(1): 371 - 380.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Sanchez-Perez, T. Kottke, G. A. Daniels, R. M. Diaz, J. Thompson, J. Pulido, A. Melcher, and R. G. Vile
Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas
J. Immunol., September 15, 2006; 177(6): 4168 - 4177.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Otahal, T. D. Schell, S. C. Hutchinson, B. B. Knowles, and S. S. Tevethia
Early Immunization Induces Persistent Tumor-Infiltrating CD8+ T Cells against an Immunodominant Epitope and Promotes Lifelong Control of Pancreatic Tumor Progression in SV40 Tumor Antigen Transgenic Mice.
J. Immunol., September 1, 2006; 177(5): 3089 - 3099.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl
A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model
J. Immunol., July 1, 2006; 177(1): 155 - 161.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Kaufman and J. D. Wolchok
Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
J. Clin. Oncol., May 20, 2006; 24(15): 2230 - 2232.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Ji, D. Gondek, and A. A. Hurwitz
Provision of Granulocyte-Macrophage Colony-Stimulating Factor Converts an Autoimmune Response to a Self-Antigen into an Antitumor Response
J. Immunol., August 1, 2005; 175(3): 1456 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Paschen, M. Song, W. Osen, X. D. Nguyen, J. Mueller-Berghaus, D. Fink, N. Daniel, M. Donzeau, W. Nagel, H. Kropshofer, et al.
Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2-Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice
Clin. Cancer Res., July 15, 2005; 11(14): 5241 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Sanchez-Perez, T. Kottke, R. M. Diaz, A. Ahmed, J. Thompson, H. Chong, A. Melcher, S. Holmen, G. Daniels, and R. G. Vile
Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of Melanocytes In vivo
Cancer Res., March 1, 2005; 65(5): 2009 - 2017.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. J. Prasad, K. J. Farrand, S. A. Matthews, J. H. Chang, R. S. McHugh, and F. Ronchese
Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells
J. Immunol., January 1, 2005; 174(1): 90 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. De Palma, I. Marigo, F. Del Galdo, C. De Santo, P. Serafini, S. Cingarlini, T. Tuting, J. Lenz, G. Basso, G. Milan, et al.
Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor {alpha} Usage by Melanoma-specific CD8+ T Lymphocytes
Cancer Res., November 1, 2004; 64(21): 8068 - 8076.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Lane, J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan
Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin
Cancer Res., February 15, 2004; 64(4): 1509 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, B. Macino, O. Marin, and P. Zanovello
Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase
J. Immunol., December 15, 2003; 171(12): 6396 - 6405.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Negroiu, R. A. Dwek, and S. M. Petrescu
The Inhibition of Early N-Glycan Processing Targets TRP-2 to Degradation in B16 Melanoma Cells
J. Biol. Chem., July 11, 2003; 278(29): 27035 - 27042.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Hodge, D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom
Vaccine Therapy of Established Tumors in the Absence of Autoimmunity
Clin. Cancer Res., May 1, 2003; 9(5): 1837 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice
J. Immunol., April 15, 2003; 170(8): 4273 - 4280.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Kalat, Z. Kupcu, S. Schuller, D. Zalusky, M. Zehetner, W. Paster, and T. Schweighoffer
In Vivo Plasmid Electroporation Induces Tumor Antigen-specific CD8+ T-Cell Responses and Delays Tumor Growth in a Syngeneic Mouse Melanoma Model
Cancer Res., October 1, 2002; 62(19): 5489 - 5494.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. Tsao, P. Millman, G. P. Linette, F. S. Hodi, A. J. Sober, M. A. Goldberg, and F. G. Haluska
Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1-Transduced Dendritic Cell Vaccine for Metastatic Melanoma
Arch Dermatol, June 1, 2002; 138(6): 799 - 802.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. van Elsas, R. P.M. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J.-P. Medema, W. W. Overwijk, N. P. Restifo, C. J.M. Melief, R. Offringa, et al.
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy
J. Exp. Med., August 20, 2001; 194(4): 481 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Demidem, D. Morvan, J. Papon, M. De Latour, and J. C. Madelmont
Cystemustine Induces Redifferentiation of Primary Tumors and Confers Protection against Secondary Tumor Growth in a Melanoma Murine Model
Cancer Res., March 1, 2001; 61(5): 2294 - 2300.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. K. Mendiratta, G. Thai, N. K. Eslahi, N. M. Thull, M. Matar, V. Bronte, and F. Pericle
Therapeutic Tumor Immunity Induced by Polyimmunization with Melanoma Antigens gp100 and TRP-2
Cancer Res., February 1, 2001; 61(3): 859 - 863.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H. Zheng, P. Palese, and A. García-Sastre
Antitumor Properties of Influenza Virus Vectors
Cancer Res., December 1, 2000; 60(24): 6972 - 6976.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.